Page last updated: 2024-12-11

n-oleoylglycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

oleoylglycine: long chain fatty acyl glycine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-oleoylglycine : A fatty acid derivative that is the 9Z-octadecenoyl derivative of glycine. It is believed to be an intermediate in oleamide biosynthesis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6436908
CHEMBL ID226118
CHEBI ID73723
SCHEMBL ID1104998
MeSH IDM0506156

Synonyms (38)

Synonym
einecs 220-009-5
ema-1
n-(9z-octadecenoyl)-glycine
n-oleoyl glycine
LMFA08020082
NCGC00161200-02
2601-90-3
n-oleoylglycine
chebi:73723 ,
CHEMBL226118
oleoyl glycine
2-[[(z)-octadec-9-enoyl]amino]acetic acid
n-[(9z)-octadec-9-enoyl]glycine
[(9z)-octadec-9-enoylamino]acetic acid
(z)-n-(1-oxo-9-octadecenyl)glycine
SCHEMBL1104998
oleoylglycine
HMS3649J07
AKOS027320432
2-[(9z)-octadec-9-enamido]acetic acid
AS-65265
n-oleoylglycine, >=98%
2-oleamidoacetic acid
acylglycine 18:1(9z)
no-gly
n-oleoylglycine, powder
Q27144069
E75903
sr-01000946664
SR-01000946664-1
HY-113204
CS-0059311
glycine, n-[(9z)-1-oxo-9-octadecen-1-yl]-
bdbm50537018
2-oleamidoaceticacid
DTXSID201317121
CAA60190
oleoylglycine, n-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
fatty amideA monocarboxylic acid amide derived from a fatty acid.
N-acylglycine 18:1An N-acylglycine in which the acyl group contains 18 carbons and 1 double bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium- and chloride-dependent glycine transporter 1Homo sapiens (human)IC50 (µMol)30.00000.000412.2769106.0000AID1638479
Sodium- and chloride-dependent glycine transporter 2Homo sapiens (human)IC50 (µMol)0.50000.026012.7472128.0000AID1638480; AID1638510
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
negative regulation of NMDA glutamate receptor activitySodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
neurotransmitter transportSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
glycine transportSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
positive regulation of hemoglobin biosynthetic processSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
regulation of synaptic transmission, glycinergicSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
positive regulation of heme biosynthetic processSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
transport across blood-brain barrierSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
glycine import across plasma membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
sodium ion transmembrane transportSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
synaptic transmission, glycinergicSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
neurotransmitter transportSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
chemical synaptic transmissionSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
synaptic transmission, glycinergicSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
glycine import across plasma membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
sodium ion transmembrane transportSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
glycine transmembrane transporter activitySodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
glycine:sodium symporter activitySodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
glycine:sodium symporter activitySodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
metal ion bindingSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
endosomeSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
plasma membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
basal plasma membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
postsynaptic densitySodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
basolateral plasma membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
apical plasma membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
lateral plasma membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
synaptic vesicle membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
dense core granuleSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
presynaptic membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
postsynaptic membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
parallel fiber to Purkinje cell synapseSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
plasma membraneSodium- and chloride-dependent glycine transporter 1Homo sapiens (human)
endosomeSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
plasma membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
dense core granuleSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
presynaptic membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
glycinergic synapseSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
plasma membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1638470Drug degradation in rat plasma at 1000 ng/ml measured over 240 mins by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
AID287964Antiproliferative activity against LPS-induced mouse RAW264.7 cells assessed as number of cells at 10 uM after 48 hrs2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID574406Cytotoxicity against human HaCaT cells at 50 to 100 uM after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads.
AID1638481Inhibition of recombinant human GlyT2a expressed in Xenopus laevis oocytes assessed as reduction in channel current by two-electrode voltage clamp electrophysiology relative to control2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
AID1638471Degradation half life in rat plasma at 1000 ng/ml by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
AID1638510Reversible non-competitive inhibition of human GlyT2a expressed in Xenopus laevis oocytes by two-electrode voltage clamp electrophysiology2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
AID287962Antiproliferative activity against LPS-induced mouse RAW264.7 cells assessed as number of cells at 0.1 uM after 48 hrs2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID287963Antiproliferative activity against LPS-induced mouse RAW264.7 cells assessed as number of cells at 1 uM after 48 hrs2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID574405Antiinflammatory activity against IFN-gamma-stimulated human HaCaT cells assessed as inhibition of chemokine MDC production at 50 to 100 uM after 18 hrs by ELISA2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads.
AID1638473Degradation half life in human plasma at 1000 ng/ml by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
AID1638472Drug degradation in human plasma at 1000 ng/ml measured over 240 mins by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
AID1638479Inhibition of recombinant human GlyT1b expressed in Xenopus laevis oocytes assessed as reduction in channel current by two-electrode voltage clamp electrophysiology2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
AID1638480Inhibition of recombinant human GlyT2a expressed in Xenopus laevis oocytes assessed as reduction in channel current by two-electrode voltage clamp electrophysiology2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (6.67)18.2507
2000's4 (26.67)29.6817
2010's6 (40.00)24.3611
2020's4 (26.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.36 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]